A second patient has died after receiving the gene therapy Elevidys, which was approved by the Food and Drug Administration (FDA) over concerns of staffers, according to the company that makes it.
The 15-year-old boy who died, and the 16-year-old boy whose death was reported earlier in the year, had both received Elevidys, the only gene therapy approved by the FDA for the treatment of a rare form of muscular dystrophy called Duchenne muscular dystrophy (DMD), Sarepta officials said in a call on June 16.
The boys were both non-ambulatory and both died within 90 days of treatment, according to Sarepta.
The 15-year-old died from acute liver failure, Sarepta said in a statement on Sunday. Acute liver injury is listed as a side effect of the product….